EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control Not yet recruitingThis trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New PET scan could predict who benefits from targeted lung cancer therapy
Disease control Not yet recruitingThis study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Zhou Chengzhi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
AI reads scans and genes to predict lung cancer drug success
Knowledge-focused Not yet recruitingThis study uses artificial intelligence to analyze CT scans, pathology slides, and genetic reports from 1,000 lung cancer patients with EGFR mutations. The goal is to build a model that predicts how well targeted therapy will work after surgery. If successful, it could help docto…
Matched conditions: EGFR ACTIVATING MUTATION
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC